Hiroshi Hirai
Tsukuba, 3000034, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer.
Journal: Investigational new drugs
Published: December 18, 2025
Examination of the relationship between participation in salons aimed at care prevention through the promotion of social participation and the subsequent cost of care: A 3-year prospective follow-up study in JAGES.
Journal: Archives of gerontology and geriatrics
Published: August 31, 2024
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Journal: Cancers
Published: May 24, 2023
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Journal: ACS medicinal chemistry letters
Published: January 12, 2023
Neighbourhood transportation, elapsed years, and well-being after surrendering the driver's licence in older Japanese adults: The JAGES longitudinal study.
Journal: Archives of gerontology and geriatrics
Published: July 26, 2022
Differences in risk of requiring care between screening using queries with and without definitions when determining frequency of going out
Journal: [Nihon koshu eisei zasshi] Japanese journal of public health
Published: May 11, 2022
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Journal: Cancer science
Published: April 08, 2022
Physical Activity and Cumulative Long-Term Care Cost among Older Japanese Adults: A Prospective Study in JAGES.
Journal: International journal of environmental research and public health
Published: March 19, 2021
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Journal: Investigational new drugs
Published: September 04, 2020
Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design.
Journal: Molecular cancer therapeutics
Published: January 21, 2020
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Journal: Cancer research
Published: October 29, 2019
The Risk of Functional Limitations After Driving Cessation Among Older Japanese Adults: The JAGES Cohort Study.
Journal: Journal of epidemiology
Published: June 25, 2019
Last Updated: 09/26/2026